Although some research over the last decade has suggested an association between depressive disorders and impaired cell-mediated immunity (CMI), results have been inconsistent (see Hickie et al, 1990; Stein eta!, 1991) . This may reflect limitations in previous studies in the breadth of assessment of immune functions and a failure to examine for the possible differential effects of depressive subtypes (Hickie eta!, 1990; Stein eta!, 1991) . Notably, in the largest study yet published, Schleifer et a! (1989) found no differences in CMI measures between 91 patients with major depression and nonnal control subjects, matched for age and sex. The patients in that study were mainly young female out-patients and the potential relevance of subtypes of depression was not examined.
The current literature suggests that disturbance of CMI in patients with depression may be related to increasing age, symptom severity, and hospital admission (Hickie et a!, 1990; Stein et al, 1991) . As these characteristics are typical of patients with melancholia (Parker et a!, 1990) , we hypothesised that immune dysfunction may be limited largely to that depressive subgroup. Theoretically, a number of other factors, such as significant weight loss, hypercortisolaemia, increased catecholamine turn over, and disturbed sleep pattern, may explain the putative link between melancholia and impaired CMI. Two previous studies (Cosyns eta!, 1989; Maes et a!, 1990) CMI when compared with other depressives, but failed to control adequately for the possible confounding influences of gender and age.
Previous research in this area has focused on in vitro techniques to assess CMI. Since the medical significance of abnormal in vitro findings remains unclear it may be more relevant clinically to broaden assessment techniques to include in vivo measures (Kniker eta!, 1984) . To that end, in this case-control study, we extend previous research by focusing not only on the relevance of subtypes of depression, but also on the assessment of delayed-type hyper sensitivity (DTH) skin responses. We utilised a commercially available DTH kit whose properties have been explored extensively in normal and medically-ill subjects (Anderson et a!, 1978; Kniker eta!, 1984) . In particular, specific illnesses involving the immune system such as malignancy (Reuben et a!, 1984) and autoimmune disorders (Smith et a!, 1989) have been associated with an impaired DTH response, as assessed by this test system.
Method
In total, 57 unmedicated, physically well patients who fulfilled DSMâ€"IIIâ€"R (American Psychiatric Association, 1987 ) criteria for a current major depressive episode were drawn from the in-patient and out-patient services of the teaching hospitals of the University of New South Wales.
Thesefacilitiesincludea specialisedtertiaryreferralservice, the Prince Henry Mood Disorders Unit (Brodaty et a!, 1987) , which provides a state-wide service for the assessment and treatmentof affectivedisorders.Noneof thesepatients had undergone previous investigations of their immune function.
An age-and sex-matched healthy control group was recruited principally from volunteer hospital staff, affiliated personnel, and a golf and recreation club based on the hospital site attracting members primarily from the local community.
Control subjects were selected to match individual patients exactly forsexand closely forage. Previous attempts toestablish a relationship betweenimpaired cell-mediated immunity (CMI) and major mood disorders have been limited by a failure to explore the relevance of depressive subcategoriesor to assessCMI by in vivo methods. In this case-controlstudy CMI was assessed in 57 patients with major depression(31 with melancholic, 26 with non-melancholicdisorders), andin age-andsex-matchedcontrolsby bothin vitro andin vivo immunological techniques.
Compared with control subjects and patients with non-melancholic depression, patients with melancholia demonstrated reduced invivo CMI asassessed bydelayed-type hypersensitivity (DTH)skinresponses. Althoughincreasing age,severity ofdepression, hospital admission fortreatment, and reported weightloss arecorrelates ofmelancholia, noneofthesefactors alone, orincombination, accounted forthedifferences inDTH responses observed between the two depressive subtypes. These data suggest that impaired CMI in vivo may be limited tothosewithmelancholic disorders. At this stagethefactors whichaccountforthis effect are unclear.
medical officer, control subjects completed the 30-item General Health Questionnaire (Goldberg, 1979) to detect current casesof psychiatricdisturbance,with thosescoring greater than four being excluded.
Depressed patients and otherwise eligible control subjects were excluded if they had taken any psychotropic medication (other than benzodiazepines), or any other medication which might impair CMI (e.g. oral cortico steroids) in the two weeks before testing. A further exclusion criterion was evidence on history or physical examination of any other relevant physical illness (e.g. malignancy, autoimmune disease, viral illness within the last month).
Male subjects were excluded if they consumed more than 60 g alcohol per day, while a limit of 40 g wasimposedfor females.
Before immunological testing, patients with depressive disorders were interviewed by a psychiatrist (IH), using a checklist of DSMâ€"IIIâ€"R criteria to assign them to the melancholic or non-melancholic subtype. Severity of depression was measured by the 21-item Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) .As with the controls, the physical health of the depressed patients was screened by a medical officer, although in some, as a conse quence of hospital admission, more exhaustive physical examinations and laboratory investigations were completed.
Informed consent for all procedures was obtained from all subjects and the study was approved by the hospital ethics committee.
CMI was tested in vivo by assessment of DTH skin responses using a commercially available kit (Multitest CMI, Merieu.x, France) whichemploys seven antigens (tetanus, diphtheria, streptococcus, tuberculin, candida, tricophyton, proteus)and a glycerincontrol. The disposablekit, applied to the forearm, allows simultaneous testing of DTH to the seven preloaded antigens in a standardised and convenient fashion. Forty-eight hours after application, the induration response at each site of antigen exposure (mean of two perpendicular diameters) is measured by trained personnel. In this study, most measurements were made by various members of the research team (IH, CH, AL), who were aware whether subjects were depressed patients or controls. A small proportion of results was recorded by pathology staff who had no knowledge of the nature of the study. Therefore, most ratings were not made blind to the knowledge of the patient v. control status, although the melancholia/non-melancholia distinction was known only to the principal psychiatric investi gator (IH). The cumulative induration diameter for the test is calculated as the sum of individual reactions at each site, provided the glycerin control is negative. In addition, the number of antigens which produced a recordable induration response (@2 mm mean diameter) isrecorded. Induration diameters of less than 2 mm at any site were recorded as absent responses. Results in this study were categorised according to previously determined reference ranges generated by testing of healthy adult populations (Kniker et a!, 1984) . A cumulative diameter of less than 10 mm for males and 5 mm for females is designated as a â€˜¿ hypoergic' response, representing subjects below the fifth centile in normal population studies (Kniker et a!, 1984) . â€˜¿ Cutaneous anergy' is indicated by the absence of an induration response to any of the seven test antigens (i.e. all responses less than 2 mm), and has been reported in less than 1 @1o of the USA (Kniker et a!, 1984) and Australian populations (Frazer et a!, 1985) .
All subjects underwent morning venepuncture. Absolute and differential white cell counts were obtained by an automated cell counter (Coulter electronics, Hialeah, Florida). T-cell subset identification was performed by fluorescence-activated flow cytometry (Becton Dickinson; California) using commercially available monoclonal antibodies (Ortho Diagnostic Systems, New Jersey) to enumerate the total T-cells (CD3), helper/inducer (CD4) and suppressor/cytotoxic (CD8) subpopulations. Absolute T-cell counts were calculated using the lymphocyte count from the cell counter and the subset percentages obtained by flow cytometry. T-cell subset counts are reported for 44 patients and control subjectsonly, due to a changein the monoclonal antibody used for phenotyping (resulting in a change in sensitivity of the assay) soon after the commencement of the study.
Peripheral blood mononuclear cells were separated by Ficol-Hypaque density-gradient separation, resuspended at a final concentration of I x 106 lymphocytes per ml, and stimulated in vitro with phytohaemagglutinin (PHA: Phaseolus spp. Burroughs Wellcome, UK). The incor poration of 3H-thymidine expressed as counts per minute (cpm) was used to measure the PHA-induced blas togenesis. Results were calculated as the mean of quadruplicate cultures with background counts from unstimulated cultures subtracted (delta cpm). A dose response curve for low, intermediate, and high concen trations of PHA was plotted (0.188, 0.375, and 0.75 @og/ml respectively). Mean counts per minute (delta cpm) for PHA-induced blastogenesis assays were transformed (log10) to minimise the variance associated with raw counts.
For each subject, the maximal stimulation count was recorded (cpmâ€•@') and these values were also transformed (log10).
Multivariate analysis of variance (MANOVA) was used to test for differences between specified groups of subjects and this was applied to all depressed patients and their matched control subjects, melancholic versus non melancholic depressed patients, melancholic patients versus their age-and sex-matched control subjects, and non melancholic depressed patients versus their age-and sex matched control subjects. For comparisons of dimensional variables between patients and their individual control subjects, â€˜¿ pairwise' I-tests were used, while for comparison of melancholic and non-melancholic depressed patients, â€˜¿ between group' I-tests were used. Pearson correlations (two-tailed) were sought between a series of possible explanatory variables (age, severity of depression, hospital admission, and reported weight loss) and DTH cumulative diameter and number of sites of response. Hierarchical regression analyses were used to evaluate the relative contributions of age, severity of depression (1-IRSDscore), hospital admission, reported weight loss and depressive subtype (melancholic/non-melancholic) on cpmâ€•@' from the PHA-induced blastogenesis and, for the DTH testing, on the cumulative induration diameter (mm) Table 1 Characteristicsof depressedpatientsand healthymatched subjects assessment and one was not able to return at 48 hours to have the test response measured). When compared with control subjects, only patients with melancholia showed impaired CMI in vivo as determined by both the total induration diameter and the number of sites of response to the DTH skin test (Table 2 ). There were 54Â¾(7/13) of male and 53Â¾(8/15) of female patients with melancholia who had categorically impaired DTH induration responses, as assessed by an induration diameter of less than 10 mm for males and 5 mm for females.
The correlations between age, depression severity (HRSD score), hospital admission, reported weight loss, and diagnosis of melancholia and DTH responses (both induration diameter and number of responses) among all depressed patients are shown in Table 3 To explore further the possible confounding effects of age, depression severity, hospital admission for treatment, and reported weight loss on DTH (mm and number of response sites) results, each of these variables was added into a hierarchical regression analysis, before depressive subtype (melancholia v. non-melancholia) was added at the final step. With regard to each measure of DTH (mm and number of sites) response, the beta weights of the potential predictive factors are shown in Table 3 . Importantly, all four non-specific factors (i.e. age, depression severity, hospital admission for treatment, and reported weight loss) accounted for 9.8% of the variance in DTH (mm) results (F= 1.30, NS), while the addition of the diagnostic information (melancholia v. non-melancholia), increased the explanatory power of the regression equation by a further 9.5% to 19.3% (F=2.26, P=0.06).
Further, age and number of skin responses. Each set of analyses (cpmâ€•@, DTH) was conducted among all depressed patients.
Resufts
The characteristics of depressed patients and their matched control subjects are shown in (7lÂ°lo) v. 14/26 (54Â¾), x2= 1.12, NS).
In vivo CMI measures
The DTH skin results were available for all 57 matched control subjects and for 54 of the depressed subjects (two patients refused consent for this aspect of the immune Table 2 Delayed-typehypersensitivity (DTH)skin responsein depressedpatients and healthy control subjects Table 3 (a) Pearson correlations between non-specific factors (age, depression severity and reported weightloss) and invivo and in vitro measuresof cell-mediatedimmunity, and (b) Beta weights from hierarchical regression equations to determinethe relativecontributionsof non-specificfactors (age,severity of depression,hospital admission,reported weight loss)ascomparedwith the diagnosisof melancholia tothevariance inbothinvivoand invitro measuresofcell and diagnostic subtypes have effects in the opposite direction. For the number of DTH response sites, the four non-specific factors account for only 5.2% (F= 0.65, NS) of the variance, while the addition of diagnostic subtype increases the explained variance by 14.lÂ°loto 19.3% (F= 2.25, P= 0.06) . Therefore, the differences in DTH responsesbetweenpatients with and without melancholia cannot be explainedin termsof the agedifferencesbetween the two depressive groups, nor in terms of depression severity, hospital admission or reported weight loss.
In vitro CMI measures
There were no differences in total lymphocyte counts or lymphocyte subset counts between the depressed patients and their control populations or between the two depressive subtypes and their control subjects (Table 4) . Results of the lymphocyte stimulation with PHA were available for 52 of the patients (30 melancholics, 22 non melancholics), as this biological assay was unsuccessful in five patients (as determined by a failure to induce a lymphocyte proliferation in a standard laboratory control which accompanied all testing of research subjects). As in most previous studies, cpmâ€• was inversely correlated with age, and showed similar trends with regard to depression severity and reported weight loss among the depressed patients (Table 3 ). In normal control subjects, however, there was no clear reduction in cpmmaxwith increasing age (r= â€"¿ 0.14, NS).
Comparisons of transformed PHA (delta cpm) results for the total patient sample versus control subjects, for the two depressive subtypes, and for each depressive subtype versus its matched normal control are shown in Table 5 . Comparisons are made both by MANOVA for overall differences between groups and by t-tests for differences at each concentration of PHA. There was no main effect (MANOVA) when the total group of depressives was compared with the control subjects (F= 1.65, NS), suggesting that a depressive diagnosis perse is not associated with a reduced lymphocyte proliferation response to PHA.
NB. For DTH results, age and the diagnosisof melancholiashow effects in opposite directions, whereasforcpmâ€•', age and diagnosis tend to have effects in the same direction, suggestin9 that increasing agemay tendtoexplain differences incpmâ€•, butnot DTH skin results, between melancholic and non-melancholic subjects. 1. DTH skin results: cumulative diameter (mm) of delayed-type hypersensitivityskin responseandnumberof positiveresponsesites. 2. cpmâ€•':maximal incorporation of 3H-thymidine,expressedas counts per minute (log,0) was used to measurethe PHA-induced blastogenesis. 3. Depressionseverity assessedwith 21-item HRSD.
4. Melancholia according to DSM-lll-R criteria. Table 4 Mean (s.d.) absolutelymphocyte countsand T-cell subsetsindepressedpatients and matched subjects The MANOVA comparing patients with depressive subtypes showed a trend (F= 3.36, P= 0.07) for those with melancholia to demonstrate an impaired blastogenic response when compared with those with non-melancholic disorders (Table 5) . This difference was most evident at the highest concentration of PHA (Table 5 ).
When patients with melancholia were compared with their own age-and sex-matched control subjects, a lower response at the highest concentration of PHA and a trend towards lower epm@â€• was again noted (Table 5) , although the MANOVA demonstrated a weak trend only towards a main effect due to the diagnosis of melancholia (F= 2.55,
P= 0.12).There wasno suggestionat all of any difference
in the MANOVA comparing non-melancholic patients and their age-and sex-matched controls (F= 0.00, NS). This pattern of results suggests an impairment of both the pattern of the PHA doseâ€"response curve and cpmâ€•@' in melancholic patients, but when compared with age-and sex matched controls, any impairment was slight. These data, however, provide no evidence of impairment of the lymphocyte response to PHA in patients with non melancholic depression. In the hierarchical regression analysis for all depressed patients age, depression severity, hospital admission, and reported weight loss accounted for 11.8% of the variance Table 3 ), while the addition of depressive subtypes at the final step increased the percentage of the variance explained by a further 6.4Â°/s to 18.2Â°/s (F=2.05, P=0.09). By contrast with the DTH results, the beta weights of age and diagnosis of depressive subtype were in the same direction, suggesting that both increasing age and depressive subtypes contribute to the observed differences in cpmhl@ax.
(F= 1.58, NS) (individual beta weights are shown in

Discussion
This study demonstrates in vivo impairment of CMI in patients with melancholia. Patients with melancholic depression had a high rate of abnormally reduced DTH induration diameter (54%) when compared with both non-melancholic patients (15%) and with age-and sex-matched control subjects (13%). By contrast, patients with non-melancholic disorders show no evidence of impaired CMI on in vivo or in vitro testing, raising the possibility that negative studies in the past (Albrecht et a!, 1985;
Schleifer et a!, 1989) may have incorporated disproportionate numbers of patients with that subtype of depression.
At this stage the mechanism(s) by which melan cholic disorders may result in immune dysfunction are unclear.
It is important to consider possible alternative explanations of our findings. Patients with melancholia were, on average, ten years older than patients without melancholia. As in vitro measures of CMI commonly decline with age (as was the case in this sample), it was important to consider whether the reduced DTH responses in melancholic patients were simply a function of their older age. In fact, there was no decline in DTH skin responses with increasing age among depressives or normal control subjects. Patients with melancholia over 50 years of age tended to have larger DTH (mm) skin responses than patients with melancholia aged 50 years or less. Hierarchical regression analyses demonstrated that a diagnosis of melancholia continued to make a contribution to the variance in DTH responses beyond that explained by age and other potentially important non-specific factors (depression severity, hospital admission, and reported weight loss).
Other possible non-specific mechanisms that may explain the differences in DTH results that were not excluded in this study include specific forms of sleep disturbance (e.g. shortened REM-latency), impaired nutrition, or increased tobacco or alcohol use. Similarly, melancholic patients may have had longer periodsor higherdoses of previouspharmaco therapy. While it remains important to control for as many of these factors as possible, and to evaluate longitudinally their relative contributions, we suspect that it is more likely that a specific biochemical parameter that is closely linked to the melancholic state (possibly increased catecholamine turnover) accounts for the observed differences in DTH responses.
Potential influences of disturbed hypothalamic-pituitary axis function, hypercorti solism and/or disturbed catecholamine turnover have all been suggested (Hickie et a!, 1990; Macs et a!, 1990; Stein et a!, 1991) .
As the measurements of DTH skin responses were not necessarily performed blind to the knowledge of whether the subject was a depressed patient or a normal control subject, and as one of the psychiatric investigators was also aware of the melancholia/non melancholia distinction, caution is required in the interpretation of the results. While we feel that observer bias is an unlikely explanation of the differences recorded (given the number of patients investigated, the number of investigators making recordings, and the size of the differences between the groups), replication of our results within our own service and by other investigators is clearly required.
Critics of the area of psychoimmunology have suggested that any reported in vitro differences between depressed patients and controls are unlikely to be of functional, or medical, significance (Denman, 1986; Hall, 1985 Hall, , 1987 . Conventional approaches to the assessment of DTH have been hampered by a lack of standardised antigens, variability in previous exposure to specific antigens within any target population, and lack of agreement as to the exact method for administering the antigenic challenge. The CMI Multitest system, however, is a robust and standardised measure which has been evaluated within North American, European, and Australian populations with the rate of cutaneous anergy being less than 1% in healthy adults (Kniker eta!, 1984; Frazer eta!, 1985) . This in vivo measure of CMI has been shown to be impaired in a wide range of disorders known to be associated with clinically significant immunological disturbance. Evaluation of the Multitest method as compared with conventional antigen batteries in 403 cancer patients (Reuben et a!, 1984) , suggested that the former method was easier to administer, subject to less variation (as a result of the simultaneous application method), and was better tolerated by patients. Of these patients with malignancies, 19% had cutaneous anergy.
Importantly, the predictive validity of the measure has been examined in patients undergoing gastro intestinal surgery. Those with an impaired CMI response develop a higher rate of post-operative infectious complications (Lorenzi, 1979) . These studies lend weight to the possibility that the DTH abnormalities we have detected in melancholia may have clinical significance as possible predictors of future risk of physical illness. Since this is the first study reporting these findings, our DTH data require replication and extension. Future studies should examine the longitudinal relationships between depression and impaired DTH, noting in particular the effects of physical treatments, as well as the relevance of DTH abnormalities in predicting future physical illness in patients with melancholia. We have argued elsewhere (Hickie et a!, 1990) 
eta!, 1991). While the hierarchical regression analysis
for PHA blastogenesis (cpmm@) suggests that such factors, notably increasing age, may account for part of the observed differences between the two depressive subtypes, the diagnosis of melancholia continued to contribute an independent effect. An alternative explanation is that the diagnosis of melancholia is actually a higher order variable (being correlated with increasing age, increasing depression severity, and increased hospital admission) and may by itself account for the apparent effects of these other factors on immune function. The significance of the diagnosis of melancholia in determining impaired CMI is supported by two previous studies which have taken into account depressive subtyping in assessing in vitro mitogen responsiveness (Cosyns et a!, 1989;  Macs et a!, 1990).
The demonstration of impaired CMI in patients with melancholia may help to explain an observed increase in physical morbidity and mortality among depressed patients (Murphy et a!, 1989) , and especially among older depressives (Bruce & Leaf, 1989 ). Further, it may help to explain an apparent increased rate of malignancies in a population with depressive symptoms who have been studied prospectively (Shekelle & Raynor, 1981 (Jankovic, 1985; Hall et a!, 1985; Besedovsky, 1985) . The potential importance of studying certain depressive subtypes such as melancholia, which is highlighted in this report, rather than more heterogeneous depressive disorders, is that links may be made between immune dys function and other biological parameters (particularly cortisol, catecholamine and/or neuropeptide metabolism) which may provide a better under standing of the central mechanisms underlying particular forms of depression.
